Holen Sie sich die Stockscreener-App
49.63
1.20%
0.59
Handel nachbörslich:
49.45
-0.18
-0.36%
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
GSK plc (ADR): Defensive Pharma Heavyweight Tests Investor Patience As Street Turns Selectively Bull - AD HOC NEWS
The Truth About GSK plc (ADR): Is This ‘Boring’ Stock Quietly Becoming a Power Play? - AD HOC NEWS
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Benzinga
The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast? - AD HOC NEWS
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally - ts2.tech
HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target - Finviz
Why is GSK plc (GSK) One of the Best Affordable Healthcare Stocks to Buy Now? - Finviz
Bard Financial Services Inc. Purchases 23,400 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Price History & Data - Traders Union
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of “Hold” by Brokerages - Defense World
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK - Sahm
Douglas Lane & Associates LLC Sells 196,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Sahm
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc - ts2.tech
A Look Into GSK Inc's Price Over Earnings - Sahm
FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year - Sahm
GSK (NYSE:GSK) Major Shareholder Plc Gsk Purchases 1,470,000 Shares - Defense World
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms - ts2.tech
GSK (NYSE:GSK) Major Shareholder Purchases 1,470,000 Shares - MarketBeat
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU - Finviz
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead - ts2.tech
GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus - ts2.tech
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back - Sahm
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea - Finviz
GSK (GSK) Scores Win in the Form of Lung Cancer Drug's Orphan Drug Designation - Finviz
GSK (GSK) Scores Win in the Form of Lung Cancer Drug’s Orphan Drug Designation - Insider Monkey
GSK (NYSE:GSK) Share Price Passes Above 200-Day Moving Average – Here’s Why - Defense World
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer - Finviz
Is GSK PLC Gaining or Losing Market Support? - Sahm
13 Best ADR Stocks to Invest In - Insider Monkey
Best International Companies to Own: 2026 Edition - Morningstar
J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Finviz
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating - ts2.tech
GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts - ts2.tech
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Sahm
Analysts Offer Predictions for GSK's Q2 Earnings (NYSE:GSK) - MarketBeat
Quantbot Technologies LP Has $5.33 Million Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK) - ts2.tech
Here's Why GSK (GSK) is a Strong Growth Stock - Yahoo Finance
GSK PLC Sponsored ADR $GSK Shares Acquired by Fisher Asset Management LLC - MarketBeat
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025 - ts2.tech
0.47%
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):